Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
NTRB 
Nutriband Inc (NTRB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: NTRB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $15
1 Year Target Price $15
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -60.99% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 71.96M USD | Price to earnings Ratio - | 1Y Target Price 15 |
Price to earnings Ratio - | 1Y Target Price 15 | ||
Volume (30-day avg) 1 | Beta 1.29 | 52 Weeks Range 3.72 - 11.78 | Updated Date 08/29/2025 |
52 Weeks Range 3.72 - 11.78 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.9 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -211.78% |
Management Effectiveness
Return on Assets (TTM) -36.45% | Return on Equity (TTM) -108.02% |
Valuation
Trailing PE - | Forward PE 370.37 | Enterprise Value 69275549 | Price to Sales(TTM) 30 |
Enterprise Value 69275549 | Price to Sales(TTM) 30 | ||
Enterprise Value to Revenue 28.88 | Enterprise Value to EBITDA -4.55 | Shares Outstanding 11130300 | Shares Floating 3097109 |
Shares Outstanding 11130300 | Shares Floating 3097109 | ||
Percent Insiders 76.37 | Percent Institutions 3.12 |
Upturn AI SWOT
Nutriband Inc
Company Overview
History and Background
Nutriband Inc. focuses on developing transdermal and topical delivery systems for various applications. Founded with the aim of improving medication adherence and providing controlled-release drug delivery solutions. Recent focus on its AVERSA abuse-deterrent transdermal technology.
Core Business Areas
- Transdermal Technology: Development and commercialization of transdermal drug delivery systems, including abuse-deterrent technologies like AVERSA.
- Nutritional Supplements: Development and distribution of transdermal nutritional supplements, aimed at improving absorption and compliance.
Leadership and Structure
The company's leadership team includes individuals with experience in pharmaceutical development, business management, and sales. Organizational structure is typical of a small public company.
Top Products and Market Share
Key Offerings
- AVERSA Technology: Abuse-deterrent transdermal technology designed to prevent opioid abuse. Market share is dependent on FDA approval and commercialization. The competitors for this product depend on what indication they intend to use it for, for example: Collegium Pharmaceutical, Inc. (COLL) and Teva Pharmaceutical Industries Ltd. (TEVA)
- Nutriband Patch: Transdermal patch for nutritional supplements. Limited market share compared to traditional supplement forms. Competitors include companies that sell transdermal vitamins such as patchMD, and MaryRuth Organics.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated. Transdermal drug delivery is a growing market segment, with increasing demand for abuse-deterrent formulations.
Positioning
Nutriband Inc. is positioned as an innovator in transdermal technology, particularly in the abuse-deterrent space. Its success depends on regulatory approvals and market adoption.
Total Addressable Market (TAM)
The transdermal drug delivery market is projected to reach billions of dollars, with the abuse-deterrent segment having substantial potential. Nutriband's TAM is a portion of this larger market, dependent on its specific product approvals and market penetration.
Upturn SWOT Analysis
Strengths
- Proprietary AVERSA technology
- Potential for abuse-deterrent opioid products
- Innovative transdermal delivery systems
Weaknesses
- Limited financial resources
- Dependence on regulatory approvals
- Small market share
Opportunities
- Partnerships with pharmaceutical companies
- Expansion into new therapeutic areas
- Growing demand for abuse-deterrent formulations
Threats
- Competition from larger pharmaceutical companies
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- COLL
- TEVA
- ABBV
- ENDP
Competitive Landscape
Nutriband's main advantage lies in its proprietary technology. Disadvantages include its small size and limited resources compared to competitors. AVERSA approval may disrupt the market.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to the developmental stage of its key technologies.
Future Projections: Future growth is heavily dependent on FDA approval and commercialization of AVERSA technology. Analyst estimates are not widely available.
Recent Initiatives: Focusing on securing partnerships and advancing clinical trials for AVERSA.
Summary
Nutriband Inc. is a small company with innovative transdermal technology but faces significant challenges. The success hinges on obtaining regulatory approval of AVERSA and establishing partnerships. The company must navigate a competitive landscape and limited resources. Future performance is highly uncertain but presents high potential reward if successful.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Market conditions and company performance can change rapidly. Market share data are approximate and can fluctuate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nutriband Inc
Exchange NASDAQ | Headquaters Orlando, FL, United States | ||
IPO Launch date 2017-11-30 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.nutriband.com |
Full time employees - | Website https://www.nutriband.com | ||
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company has commercial development and clinical supply agreement with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.